In the study, most people with HIV and fatty liver disease on INSTI drugs were taking dolutegravir, which made up 41% of those on INSTIs.

Scientific Claim

Among people with HIV and non-alcoholic fatty liver disease receiving integrase inhibitor therapy, dolutegravir was the most common integrase inhibitor, accounting for 41% of INSTI users.

Original Statement

“Amongst participants, 39 (64%) were on INSTI containing regimens, the most common of which was dolutegravir (41%).”

From study:1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

definitive

Can make definitive causal claims

Assessment Explanation

This is a factual description of the study population, so no causal language is needed. The claim accurately reflects the data without overstatement.

Evidence from Studies

Supporting (1)

1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

Randomized Controlled Trial

Human

Contradicting (0)

No contradicting evidence found

Source Study

1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

Score: 63

DOI: 10.1093/ofid/ofad500.1334

Similar Assertions

Out of 61 people with HIV and fatty liver disease in the study, 39 were taking integrase inhibitors, and most of those (41% of all participants) were on dolutegravir.

91%

Out of 61 people with HIV and fatty liver in the study, 39 were on INSTI drugs, and most of those (41%) were taking dolutegravir.

91%

Researchers looked at data from a previous study where 61 people with HIV and fatty liver disease were given either tesamorelin or a placebo, then focused on those taking integrase inhibitor drugs.

74%

Before starting treatment, people with HIV and fatty liver disease who were taking integrase inhibitors had similar body measurements as those not taking them.

73%

People with HIV and fatty liver disease who were on INSTI drugs had similar body measurements at the start of the study compared to those not on INSTIs.

71%